Baseline demographic and clinical characteristics of the patients
| Characteristics . | Cohort . | Total (n = 31) . | ||
|---|---|---|---|---|
| AML (n = 21) . | HR-MDS (n = 6) . | Other∗ (n = 4) . | ||
| Median age (range), y | 75 (62-83) | 61.5 (52-87) | 67.5 (62-70) | 73 (52-87) |
| Age >75 y, n (%) | 9 (43) | 1 (17) | 0 (0) | 10 (32) |
| Sex, n (%) | ||||
| Male | 10 (48) | 2 (33) | 2 (50) | 14 (45) |
| Female | 11 (52) | 4 (67) | 2 (50) | 17 (55) |
| ECOG PS, n (%) | ||||
| 0 | 7 (33) | 4 (67) | 2 (50) | 13 (42) |
| 1 | 10 (48) | 2 (33) | 2 (50) | 14 (45) |
| 2 | 4 (19) | 0 (0) | 0 (0) | 4 (13) |
| AML type, n (%) | ||||
| De novo | 15 (71) | |||
| Secondary or t-AML | 6 (29) | |||
| Bone marrow blast count, n (%) | ||||
| <30% | 13 (62) | |||
| ≥30% | 8 (38) | |||
| ELN, n (%) | ||||
| Adverse risk | 14 (66) | |||
| Intermediate risk | 6 (29) | |||
| Favorable risk | 1 (5) | |||
| R-IPSS, n (%) | ||||
| High | 1 (17) | |||
| Very high | 5 (83) | |||
| Somatic mutations, n (%) | ||||
| IDH1 or IDH2 | 6 (29) | 6 (29) | ||
| NPM1 | 1 (5) | 1 (5) | ||
| FLT3 ITD | 2 (10) | 2 (10) | ||
| N/KRAS | 4 (19) | 4 (19) | ||
| TP53 | 5 (24) | 6 (100) | 11 (36) | |
| Baseline transfusion dependence, n (%) | ||||
| Red cells and/or platelets | 11 (53) | 5 (83) | 2 (50) | 18 (58) |
| Race, n (%) | ||||
| White | 12 (57) | 4 (66) | 0 (0) | 16 (52) |
| Black | 4 (19) | 1 (17) | 1 (25) | 6 (19) |
| Hispanic | 4 (19) | 1 (17) | 2 (50) | 7 (23) |
| Asian | 1 (5) | 0 (0) | 1 (25) | 2 (6) |
| Characteristics . | Cohort . | Total (n = 31) . | ||
|---|---|---|---|---|
| AML (n = 21) . | HR-MDS (n = 6) . | Other∗ (n = 4) . | ||
| Median age (range), y | 75 (62-83) | 61.5 (52-87) | 67.5 (62-70) | 73 (52-87) |
| Age >75 y, n (%) | 9 (43) | 1 (17) | 0 (0) | 10 (32) |
| Sex, n (%) | ||||
| Male | 10 (48) | 2 (33) | 2 (50) | 14 (45) |
| Female | 11 (52) | 4 (67) | 2 (50) | 17 (55) |
| ECOG PS, n (%) | ||||
| 0 | 7 (33) | 4 (67) | 2 (50) | 13 (42) |
| 1 | 10 (48) | 2 (33) | 2 (50) | 14 (45) |
| 2 | 4 (19) | 0 (0) | 0 (0) | 4 (13) |
| AML type, n (%) | ||||
| De novo | 15 (71) | |||
| Secondary or t-AML | 6 (29) | |||
| Bone marrow blast count, n (%) | ||||
| <30% | 13 (62) | |||
| ≥30% | 8 (38) | |||
| ELN, n (%) | ||||
| Adverse risk | 14 (66) | |||
| Intermediate risk | 6 (29) | |||
| Favorable risk | 1 (5) | |||
| R-IPSS, n (%) | ||||
| High | 1 (17) | |||
| Very high | 5 (83) | |||
| Somatic mutations, n (%) | ||||
| IDH1 or IDH2 | 6 (29) | 6 (29) | ||
| NPM1 | 1 (5) | 1 (5) | ||
| FLT3 ITD | 2 (10) | 2 (10) | ||
| N/KRAS | 4 (19) | 4 (19) | ||
| TP53 | 5 (24) | 6 (100) | 11 (36) | |
| Baseline transfusion dependence, n (%) | ||||
| Red cells and/or platelets | 11 (53) | 5 (83) | 2 (50) | 18 (58) |
| Race, n (%) | ||||
| White | 12 (57) | 4 (66) | 0 (0) | 16 (52) |
| Black | 4 (19) | 1 (17) | 1 (25) | 6 (19) |
| Hispanic | 4 (19) | 1 (17) | 2 (50) | 7 (23) |
| Asian | 1 (5) | 0 (0) | 1 (25) | 2 (6) |
ECOG PS, Eastern Cooperative Oncology Group performance status; ELN, European leukemia index; R-IPSS, revised international prognostic scoring system; t-AML, therapy-related AML.
Patients with MDS/myeloproliferative neoplasm, chronic myelomonocytic leukemia, and myelofibrosis.